Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-3 R alpha

IL-3 R alpha

Brief Information

Name:Interleukin-3 receptor subunit alpha
Target Synonym:IL3RY,IL-3RA,CD123 Antigen,IL3RX,IL-3R Subunit Alpha,IL3R,IL-3 Receptor Subunit Alpha,IL-3 Receptor Alpha SP2 Isoform,Interleukin 3 Receptor Subunit Alpha,IL3RAY,IL-3R-Alpha,CD123,HIL-3Ra,IL3RA,Interleukin 3 Receptor, Alpha (Low Affinity),Interleukin-3 Receptor Subunit Alpha,Interleukin-3 Receptor alpha Subunit
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:36
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
ILA-HA2H8 Human APC-Labeled Human IL-3 R alpha / CD123 Protein, His Tag (Site-specific conjugation)
ILA-HA2H8-structure
ILA-H8214 Human Biotinylated Human IL-3 R alpha / CD123 Protein, Avitag™ (MALS verified)
ILA-H8214-structure
ILA-H8214-sds
ILA-HP2H8 Human PE-Labeled Human IL-3 R alpha / CD123 Protein, His Tag (Site-specific conjugation)
ILA-HP2H8-structure
ILA-H82F3 Human Biotinylated Human IL-3 R alpha / CD123 Protein, Fc,Avitag™ (MALS verified)
ILA-H82F3-structure
ILA-H82F3-sds
ILA-HF253 Human FITC-Labeled Human IL-3 R alpha / CD123 Protein, Fc Tag
ILA-HF253-structure
ILA-HF253-sds
ILA-H5252 Human Human IL-3 R alpha / CD123 Protein, Fc Tag (MALS & SPR verified)
ILA-H5252-structure
ILA-H5252-sds
ILA-C52H3 Canine Canine IL-3 R alpha / CD123 Protein, His Tag
ILA-C52H3-structure
ILA-C52H3-sds
ILA-H82H5 Human Biotinylated Human IL-3 R alpha / CD123 Protein, His,Avitag™, premium grade
ILA-H82H5-structure
ILA-H82H5-sds
ILA-HF2H9 Human FITC-Labeled Human IL-3 R alpha / CD123 Protein, His Tag
ILA-HF2H9-structure
ILA-HF2H9-sds
ILA-M52H4 Mouse Mouse IL-3 R alpha / CD123 Protein, His Tag (SPR verified)
ILA-M52H4-structure
ILA-M52H4-sds
ILA-C52H6 Cynomolgus Cynomolgus IL-3 R alpha / CD123 Protein, His Tag (SPR verified)
ILA-C52H6-structure
ILA-C52H6-sds
ILA-H5255 Human Human IL-3 R alpha / CD123 Protein, Llama IgG2b Fc Tag, low endotoxin
ILA-H5255-structure
ILA-H5255-sds
ILA-H52H6 Human Human IL-3 R alpha / CD123 Protein, His Tag (MALS & SPR verified)
ILA-H52H6-structure
ILA-H52H6-sds
ACRO Quality

Part of Bioactivity data

ILA-HA2H8-Cell-based assay
IL-3 R alpha FACS

5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human IL-3 R alpha Protein, His Tag (Cat. No. ILA-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

Protocol
ILA-HP2H8-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human IL-3 R alpha, His Tag (Cat. No. ILA-HP2H8) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol
ILA-H5252-SPR
IL-3 R alpha SPR

Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol
ILA-M52H4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Mouse IL-3 R alpha, His Tag (Cat. No. ILA-M52H4) on CM5 Chip can bind Mouse IL-3 Protein, His Tag (Cat. No. IL3-M52H8) with an affinity constant of 0.929 μM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol

Customer Reviews

Synonym Name

IL3R,IL3RA,IL-3Ra,IL-3R-alpha,IL3RAY,IL3RX,IL3RY,CD123 antigen,CD123,hIL3Ra,hIL-3Ra,MGC34174,IL-3 R alpha

Background

Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tagraxofusp SL-401; DTIL-3; DT388 IL3 Approved Texas A&M University Development Foundation Elzonris United States Blastic Plasmacytoid Dendritic Cell Neoplasm Stemline Therapeutics Inc 2018-12-21 Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma Details
Tagraxofusp SL-401; DTIL-3; DT388 IL3 Approved Texas A&M University Development Foundation Elzonris United States Blastic Plasmacytoid Dendritic Cell Neoplasm Stemline Therapeutics Inc 2018-12-21 Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
Flotetuzumab S-80880; MGD-006; RES-234 Phase 2 Clinical Macrogenics Inc Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details
Talacotuzumab CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL Phase 2 Clinical Csl Ltd Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Vibecotamab XmAb-14045 Phase 2 Clinical Xencor Inc Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Pivekimab sunirine IMGN-632 Phase 2 Clinical Immunogen Inc Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Southwest Hospital) Phase 2 Clinical Southwest Hospital Chongqing Leukemia, Myeloid Details
AZD-9829 AZD-9829; AZD9829 Phase 2 Clinical Astrazeneca Plc Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University Leukemia, Myeloid, Acute Details
MP0533 MP0533 Phase 2 Clinical Molecular Partners Ag Leukemia, Myeloid, Acute Details
APVO-436 APVO-436; APVO436 Phase 2 Clinical Aptevo Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
SAR-443579 SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 Phase 2 Clinical Sanofi Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) JEZ-567 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia, Myeloid, Acute Details
UCART-123 UCART-123 Phase 1 Clinical Cellectis Sa Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
JNJ-63709178 JNJ-9178; CNTO-9958; JNJ-63709178 Phase 1 Clinical Johnson & Johnson Innovative Medicine, Genmab A/S Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Leukemia, Myeloid, Acute Details
IM-23 (Beijing Immunochina Medical Science and Technology) IM-23; IM-23 CAR-T Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) Phase 1 Clinical Leukemia, Myeloid, Acute Details
MB-102 (Mustang Bio) MB-102 Phase 1 Clinical Mustang Bio Inc, City Of Hope National Medical Center Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details
UniCAR-T-CD-123 UniCAR-T-CD123; AVC-101 Phase 1 Clinical AvenCell Therapeutics Inc, AvenCell Europe GmbH Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital Leukemia, Myeloid, Acute Details
CD123 CAR-T cells (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
ACLX-002 ACLX-002 Phase 1 Clinical Arcellx Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
MGD-024 MGD-024 Phase 1 Clinical Macrogenics Inc Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
AFM-28 AFM-28 Phase 1 Clinical Affimed Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute Details
VIP943 BAY-943; VIP-943 Phase 1 Clinical Bayer AG Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
CD123 CAR-NK cell therapy(Beijing JD Biotech) JD123; JD-123 Phase 1 Clinical Peking University People'S Hospital, Beijing JD Biotech Co Ltd Leukemia, Myeloid, Acute Details
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) Phase 1 Clinical Shenzhen Geno-Immune Medical Institute Leukemia, Myeloid, Acute Details
AVC-201 AVC-201; Allo-RevCAR01-T-CD123 Phase 1 Clinical AvenCell Europe GmbH Leukemia, Myeloid, Acute Details
CD123-CAR T cells(St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma Details
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) JD023 Phase 1 Clinical Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences Leukemia, Myeloid, Acute Details
BYON-4413 BYON-4413 Phase 1 Clinical Byondis Bv Hematologic Neoplasms; Leukemia, Myeloid, Acute Details
GR-1901 GR1901; GR-1901 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
SQZ-622(Novartis Pharma) SQZ-622 Phase 1 Clinical Novartis Pharma Ag Leukemia, Myeloid, Acute Details
UniCAR02-T UniCAR02-T Phase 1 Clinical Cellex Patient Treatment Gmbh Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IL3 CAR T-cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
Flotetuzumab S-80880; MGD-006; RES-234 Phase 2 Clinical Macrogenics Inc Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details
Talacotuzumab CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL Phase 2 Clinical Csl Ltd Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Vibecotamab XmAb-14045 Phase 2 Clinical Xencor Inc Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Pivekimab sunirine IMGN-632 Phase 2 Clinical Immunogen Inc Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Southwest Hospital) Phase 2 Clinical Southwest Hospital Chongqing Leukemia, Myeloid Details
AZD-9829 AZD-9829; AZD9829 Phase 2 Clinical Astrazeneca Plc Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University Leukemia, Myeloid, Acute Details
MP0533 MP0533 Phase 2 Clinical Molecular Partners Ag Leukemia, Myeloid, Acute Details
APVO-436 APVO-436; APVO436 Phase 2 Clinical Aptevo Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
SAR-443579 SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 Phase 2 Clinical Sanofi Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) JEZ-567 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia, Myeloid, Acute Details
UCART-123 UCART-123 Phase 1 Clinical Cellectis Sa Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
JNJ-63709178 JNJ-9178; CNTO-9958; JNJ-63709178 Phase 1 Clinical Johnson & Johnson Innovative Medicine, Genmab A/S Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Leukemia, Myeloid, Acute Details
IM-23 (Beijing Immunochina Medical Science and Technology) IM-23; IM-23 CAR-T Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) Phase 1 Clinical Leukemia, Myeloid, Acute Details
MB-102 (Mustang Bio) MB-102 Phase 1 Clinical Mustang Bio Inc, City Of Hope National Medical Center Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details
UniCAR-T-CD-123 UniCAR-T-CD123; AVC-101 Phase 1 Clinical AvenCell Therapeutics Inc, AvenCell Europe GmbH Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital Leukemia, Myeloid, Acute Details
CD123 CAR-T cells (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
ACLX-002 ACLX-002 Phase 1 Clinical Arcellx Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
MGD-024 MGD-024 Phase 1 Clinical Macrogenics Inc Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
AFM-28 AFM-28 Phase 1 Clinical Affimed Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute Details
VIP943 BAY-943; VIP-943 Phase 1 Clinical Bayer AG Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
CD123 CAR-NK cell therapy(Beijing JD Biotech) JD123; JD-123 Phase 1 Clinical Peking University People'S Hospital, Beijing JD Biotech Co Ltd Leukemia, Myeloid, Acute Details
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) Phase 1 Clinical Shenzhen Geno-Immune Medical Institute Leukemia, Myeloid, Acute Details
AVC-201 AVC-201; Allo-RevCAR01-T-CD123 Phase 1 Clinical AvenCell Europe GmbH Leukemia, Myeloid, Acute Details
CD123-CAR T cells(St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma Details
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) JD023 Phase 1 Clinical Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences Leukemia, Myeloid, Acute Details
BYON-4413 BYON-4413 Phase 1 Clinical Byondis Bv Hematologic Neoplasms; Leukemia, Myeloid, Acute Details
GR-1901 GR1901; GR-1901 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
SQZ-622(Novartis Pharma) SQZ-622 Phase 1 Clinical Novartis Pharma Ag Leukemia, Myeloid, Acute Details
UniCAR02-T UniCAR02-T Phase 1 Clinical Cellex Patient Treatment Gmbh Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IL3 CAR T-cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap